David Roman Appointed CEO of Acutus Medical

Acutus Medical Inc. has a new leader.

The company appointed David Roman as president, CEO, and member of the Board of Directors, effective immediately. 
 
“Since being appointed interim CEO, David has hit the ground running with an intense focus on reinvigorating the company’s strategy, driving operational improvements, and successfully completing the first close of our left-heart access portfolio sale to Medtronic and debt refinancing,” said Scott Huennekens, board chairman. “As the board considered the needs of the company, we determined that this focus as well as David’s performance over the past two months made him the right person to lead Acutus moving forward. In addition, David has demonstrated strong and engaging leadership with the senior management team as well as the board, and we are confident in David’s ability to drive long-term growth and value creation at Acutus.”
 
Roman joined the company as chief financial officer (CFO) in March 2021 and has been serving as interim CEO since May 13. He will continue to act as CFO until a replacement is hired.

“Acutus benefits from a dedicated and passionate team, and as CEO I am excited to continue driving the adoption of our electrophysiology mapping and therapy solutions as well as improving our operational and financial performance,” Roman said. “We have a tremendous amount of opportunity ahead of us, and I am confident in our ability to execute on our plans and maintain positive momentum in 2022 and beyond.”

The company also announced preliminary second quarter revenue results. It expects Q2 revenues to fall between $4 million and $4.1 million, compared to $4.7 million in the second quarter of 2021 and $3.7 million in the first quarter of 2022.
 
“We are pleased with the progress in our business through the second quarter. Our deliberate focus on procedure volumes and utilization is gaining momentum, as we achieved another quarter of record procedure volumes with growth on a both a sequential and year-over-year basis,” said Roman. “In addition, we are starting to see the benefits of our cost improvement programs with a significant decline in our second quarter 2022 cash burn when compared to the first quarter of 2022. We look forward to providing additional updates on our second quarter 2022 earnings call in August.”
 
Acutus is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a portfolio of electrophysiology products that provide customers with solutions for catheter-based cardiac arrhythmia treatment. Founded in 2011, Acutus is based in Carlsbad, Calif.